Asciminib
Back to searchMolecule Structure
Scientific Name
Asciminib
Description of the Drug
Asciminib is an inhibitor of ABL/BCR-ABL1 tyrosine kinase for the treatment of patients with Philadelphia chromosome-positive CML, including those with the T315I mutation.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB12597
http://www.drugbank.ca/drugs/DB12597
Brand Name(s)
Not Available
Company Owner(s)
Novartis Pharmaceuticals Corp
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Tyrosine-protein kinase ABL | SINGLE PROTEIN | INHIBITOR | CHEMBL1862 |
Bcr/Abl fusion protein | CHIMERIC PROTEIN | INHIBITOR | CHEMBL2096618 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL15388306 |
PharmGKB | PA166268841 |
DrugBank | DB12597 |
PubChem | 72165228 |
PDBe | AY7 |
BindingDB | 50459091 |
ChemicalBook | CB23133462 |
Guide to Pharmacology | 8962 |
ZINC | ZINC000150275965 |